The test utilizes next generation sequencing (NGS) to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization (FISH) methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci.

This multimodality cancer profiling test is unique and first of its kind and will address some of the limitations of NGS when used in a stand-alone fashion.

It will not only detect the common molecular abnormalities in specific cancers, but may also discover unexpected abnormalities that could open up new therapeutic options for physicians and their patients.

"We are committed to supporting the oncology community, not only in their day-to-day clinical practice, but also in their efforts to conquer cancers that fail conventional therapy. We also believe this new test will be warmly received by our biopharmaceutical clients to support their clinical trial programs. In this exciting era of precision medicine, we are highly focused on developing and offering innovative molecular oncology tests that provide clinically actionable results for the benefit of our clients and their patients," said Douglas VanOort, NeoGenomics’ Chairman and CEO.

NeoGenomics operates a network of CLIA-certified clinical laboratories that specialize in cancer genetics testing, the fastest growing segment of the laboratory industry.